Andrew P. Han

2 weeks ago | genomeweb.com | Andrew P. Han

NEW YORK – Spatial biology firm Vizgen recently launched an updated chemistry for its spatial transcriptomics product line that promises better performance with low-quality samples. The MERFISH (multiplexed, error-robust fluorescence in situ hybridization) 2.0 chemistry offers better detection of fragmented and other lower-quality RNAs. "The impact of this is to open up a new group of sample types," including clinical samples, said Jiang He, Vizgen cofounder and VP of R&D.

Sep 12, 2024 | precisionmedicineonline.com | Andrew P. Han

NEW YORK – Memorial Sloan Kettering Cancer Center (MSK) is in the process of implementing a new rapid sequencing-based cancer panel to complement ongoing comprehensive genomic profiling (CGP). The assay, branded as MSK-React, is based on a new panel from Pillar Biosciences, recently launched as the OncoReveal Nexus. MSK-React masks two of the 21 genes in the panel and is available in separate reported formats for solid and hematological tumors.

Dec 18, 2023 | 360dx.com | Andrew P. Han

NEW YORK – Illumina said on Monday that it plans to divest Grail by June 2024 in either a third-party sale or a capital markets transaction. The announcement comes after the US Court of Appeals for the Fifth Circuit issued a decision on Friday that sidestepped Illumina's grandest arguments about why the US Federal Trade Commission erred in April when it ordered Illumina to sell off the multi-cancer early detection test company it bought in 2021 for approximately $8 billion.

Nov 17, 2023 | 360dx.com | Andrew P. Han

SALT LAKE CITY – The Association for Molecular Pathology has asked Congress to revisit the idea of updating the Clinical Laboratory Improvement Amendments (CLIA) as an alternative to a recently proposed rule by the US Food and Drug Administration that would regulate laboratory-developed tests as medical devices. Nevertheless, the organization is bracing for the FDA to push through the rule and is preparing legal action to challenge the agency.

Nov 17, 2023 | 360dx.com | Andrew P. Han

SALT LAKE CITY – Roche has presented data on the concordance of its Avenio Tumor Tissue comprehensive genomic profiling (CGP) assay with alternative products from its Foundation Medicine subsidiary and Illumina.  In a sponsored session Wednesday at this year's annual meeting of the Association for Molecular Pathology, Roche Diagnostics Solutions Medical Affairs Lead Helle Sorensen shared data from studies comparing Avenio with the FoundationOne CDx and Illumina's TruSight Oncology (TSO) 500.